drugset / Trial / NCT00855868
Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals
Phase 2
Completed
28 enrolled
Avid Radiopharmaceuticals
American College of Radiology Imaging Network · collabGeneral Electric · collab
NaSingle-groupSingle-blindDiagnostic
Summary
This study will evaluate the performance characteristics of a novel \[18F\] amyloid detection ligand (18F\]-AV-45) with respect to its ability to distinguish patients with clinically-diagnosed probable Alzheimer's disease from cognitively normal elderly subjects and to independently compare its diagnostic performance characteristics with the ability of \[11C\]PIB to correctly categorize the same subjects. SPECIFIC HYPOTHESES 1. Individuals with a clinical diagnosis of probable Alzheimer's disease will have increased brain retention of \[18F\]-AV-45 compared to cognitively normal elderly individuals. 2. There will be no clinically meaningful difference in the amyloid retention performance characteristics of \[18F\]-AV-45 and \[l1C\]PIB.
Timeline
- Start
- 2009-03
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 11C-PiB | Diagnostic / imaging agent | 555 mbq | Intravenous |
| Subject | florbetapir F 18 | Diagnostic / imaging agent | 370 mbq | Intravenous |